Figure 2

(A) Serum biomarker levels on admission in patients surviving/dying 1 year after TBI. Number of samples in each group: Alive, n = 203; Dead, n = 18. Biomarker levels presented with different ordinate scales. (B) Serum biomarker concentrations at admission in TBI patients with favorable (GOSE ≥ 5) vs. unfavorable outcome (GOSE ≤ 4). Number of samples in each group: Favorable outcome, n = 191; unfavorable outcome, n = 28. Biomarker levels presented with different ordinate scales. (C,D) ROC curves for the ability of serum biomarkers to separate patients with TBI by (C) 1-year mortality and (D) 6–12 months functional outcome (GOSE ≤ 4 vs GOSE ≥ 5). AUC with 95% CI shown along with sensitivity and specificity at defined cut points. Nfl neurofilament light, GFAP glial fibrillary acidic protein, UCHL1 ubiquitin carboxy-terminal hydrolase L1, GOSE Glasgow outcome scale extended, ROC receiver operating characteristics, Cut cut point, Sen sensitivity, Spe specificity, AUC area under the curve.